ArticlePLOS global public health2026
Ocular manifestations of Clade Ib mpox in four South-Kivu health zones, Democratic Republic of the Congo.
Article in PLOS global public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Prevalence, characteristics, and clinical course of mpox-related ophthalmic disease (MBOTE-EYE): a prospective cohort study in South Kivu, Democratic Republic of the Congo.The Lancet. Global health · 2026Article
- Patient with longstanding mpox keratitis successfully treated with topical Cidofovir 0.5% eye drops: a case report.BMC ophthalmology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With several international outbreaks ongoing, mpox-related eye disease is increasingly detected, yet data on its prevalence remain limited. We conducted a descriptive cross-sectional study in four health zones in South-Kivu Province, Democratic Republic of the Congo, between November 1, 2024 and January 31, 2025, to describe the clinical features of mpox-related ophthalmic disease in hospitalized patients during the ongoing clade Ib outbreak. Routine ophthalmic examination was performed in laboratory-confirmed hospitalized mpox patients. The assessment included visual acuity measurement, inspection of eyelids and ocular surface with a magnifying glass, portable slit lamp biomicroscopy of the anterior segment, and ophthalmoscopy. We examined a total of 366 patients, of whom 210 (57.4%) were male. The median (IQR) age was 8 (4-16) years, 260 (71%) of the patients were younger than 15, and 168 (45.8%) were under 5. Ocular symptoms and disease were recorded in 190 (51.9%) patients. The most common ocular symptom was redness (51.9%), followed by pain (20.0%), itching (18.3%), and conjunctival discharge (16.7%). Conjunctivitis was observed in 113 (30.9%) patients. Other manifestations included blepharoconjunctivitis (7.4%), blepharitis (5.2%), and keratoconjunctivitis (3.3%). Ulcerative and non-ulcerative keratitis were present in 2.5% and 2.2% of the patients, respectively. Two (0.6%) HIV-positive patients had herpes zoster ophthalmicus. Visual impairment was recorded in 5.7% and blindness in 2.5% of the patients. Ophthalmologic manifestations were common during hospitalization in this group of patients. The early occurrence of ophthalmic manifestations requires early ophthalmic assessment for timely diagnosis and treatment to achieve better outcomes. Outbreak frontline healthcare workers should be alert of ocular symptoms such as redness, pain, sensitivity to light, and tearing in both suspected and laboratory-confirmed cases and promptly initiate an ophthalmic evaluation.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.